

Contents lists available at [ScienceDirect](#)

EBioMedicine

journal homepage: [www.elsevier.com/locate/ebiom](http://www.elsevier.com/locate/ebiom)

Corrigendum

## Corrigendum to 'Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom' ☆,☆☆



Pauline Versteegen<sup>a</sup>, Marta Valente Pinto<sup>b</sup>, Alex M. Barkoff<sup>c</sup>, Pieter G.M. van Gageldonk<sup>a</sup>, Jan van de Kasstele<sup>a</sup>, Marlies A. van Houten<sup>d</sup>, Elisabeth A.M. Sanders<sup>a,c</sup>, Ronald de Groot<sup>f</sup>, Dimitri A. Diavatopoulos<sup>f</sup>, Sagida Bibi<sup>b</sup>, Raakel Luoto<sup>c</sup>, Qiushui He<sup>c</sup>, Anne-Marie Buisman<sup>a</sup>, Dominic F. Kelly<sup>e,g</sup>, Jussi Mertsola<sup>c</sup>, Guy A.M. Berbers<sup>a,\*</sup>

<sup>a</sup> National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Antonie van Leeuwenhoeklaan 9, Bilthoven 3720 BA, the Netherlands

<sup>b</sup> University of Oxford, Department of Paediatrics, Oxford Vaccine Group, Oxford OX3 7LE, United Kingdom

<sup>c</sup> University of Turku, Institute of Biomedicine, Microbiology, Virology and Immunology, and Turku University Hospital, Turku 20500, Finland

<sup>d</sup> Spaarne Gasthuis, Spaarne Gasthuis Academy, Hoofddorp 2134 TM, the Netherlands

<sup>e</sup> Wilhelmina Children's Hospital, Department of Paediatric Immunology and Infectious Diseases, Lundlaan 6, 3584 EA Utrecht, the Netherlands

<sup>f</sup> Radboud University Medical Centre, Radboud Institute for Molecular Life Sciences, Department of Laboratory Medicine, Nijmegen 6525 GA, the Netherlands

<sup>g</sup> Oxford University Hospitals NHS Foundation Trust, Headington, Oxford OX3 9DU, United Kingdom

### Acknowledgements

We thank all participants of the study and we acknowledge the work of all individuals at the Oxford Vaccine Group, the Turku University group, the Dutch Spaarne Hospital and RIVM who have undertaken the work of the BERT study including the administrative staff, play assistants, clinical research nurses, clinical research fellows, laboratory staff and members of the IT team. In particular, we acknowledge Jacqueline Zonneveld and Greetje van Asselts at the Spaarne Gasthuis Hospital, Hoofddorp, the Netherlands for their help in the management of clinical data and performing home visits. We are also grateful to Inge Pronk and Eleonora Lambert, who both work at the Centre for Infectious Disease Control, RIVM for their assistance in clinical trial management.

PERISCOPE has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115910. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and BMGF.

DFK receives salary for support from the NIHR Oxford Biomedical Research Centre.

[EBioMedicine 65 (2021) 103247]

The authors of this Research Paper would like to update the Acknowledgements section. The new text of this section is as follows:

DOI of original article: [10.1016/j.ebiom.2021.103247](https://doi.org/10.1016/j.ebiom.2021.103247)

\* Corresponding author.

E-mail address: [guy.berbers@rivm.nl](mailto:guy.berbers@rivm.nl) (G.A.M. Berbers).

<https://doi.org/10.1016/j.ebiom.2021.103420>

2352-3964/© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).